167 related articles for article (PubMed ID: 7827902)
21. Positron Emission Tomography-Computed Tomography for Patients with Recurrent Colorectal Liver Metastases: Impact on Restaging and Treatment Planning.
Viganò L; Lopci E; Costa G; Rodari M; Poretti D; Pedicini V; Solbiati L; Chiti A; Torzilli G
Ann Surg Oncol; 2017 Apr; 24(4):1029-1036. PubMed ID: 27807727
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
23. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
[TBL] [Abstract][Full Text] [Related]
24. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
[TBL] [Abstract][Full Text] [Related]
25. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
[TBL] [Abstract][Full Text] [Related]
26. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
27. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
Ozkan E; Soydal C; Araz M; Aras G
Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
[TBL] [Abstract][Full Text] [Related]
28. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
29. The role of FDG PET/CT in patients with colorectal cancer metastases.
Kochhar R; Liong S; Manoharan P
Cancer Biomark; 2010; 7(4):235-48. PubMed ID: 21576816
[TBL] [Abstract][Full Text] [Related]
30. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
[TBL] [Abstract][Full Text] [Related]
31. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
32. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
Staib L; Schirrmeister H; Reske SN; Beger HG
Am J Surg; 2000 Jul; 180(1):1-5. PubMed ID: 11036130
[TBL] [Abstract][Full Text] [Related]
33. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods.
Ochoa-Figueroa MA; Uña-Gorospe J; Allende-Riera A; Cárdenas-Negro JC; Muñoz-Iglesias J; Cabello-García D; De Sequera-Rahola M; Martínez-Gimeno E
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):249-56. PubMed ID: 23067526
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
[TBL] [Abstract][Full Text] [Related]
35. DIAGNOSTIC ROLE OF FLUORINE-18 (18F) FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY IN DETECTING RECURRENT DISEASE IN PATIENTS WITH COLORECTAL CANCER AND ELEVATED CARCINOEMBRYONIC ANTIGEN.
Matovina E; Mihailović J; Nikoletić K; Srbovan D
Med Pregl; 2015; 68(11-12):376-81. PubMed ID: 26939303
[TBL] [Abstract][Full Text] [Related]
36. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
37. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
[TBL] [Abstract][Full Text] [Related]
38. Krukenberg tumor and lung metastases from colon carcinoma diagnosed with F-18 FDG PET.
Bohdiewicz PJ; Juni JE; Ball D; Dworkin H
Clin Nucl Med; 1995 May; 20(5):419-20. PubMed ID: 7628145
[TBL] [Abstract][Full Text] [Related]
39. Does positron emission tomography/computed tomography change management in colorectal cancer?
Falconer R; Connor S; Balasingam A; Eglinton T
ANZ J Surg; 2018 Apr; 88(4):E248-E251. PubMed ID: 27788564
[TBL] [Abstract][Full Text] [Related]
40. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.
Strasberg SM; Dehdashti F; Siegel BA; Drebin JA; Linehan D
Ann Surg; 2001 Mar; 233(3):293-9. PubMed ID: 11224615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
